Abstract
Background
The risk of chronic kidney disease stage 5 and its progression depend on the stage and the underlying diagnosis. Haemodialysis has become the long-term maintenance therapy for these patients. The interaction among interleukin-6 (IL-6), hepcidin and the iron exporter ferroportin is a major contributor to the iron-deficiency anaemia of chronic disease. The aim of the present study was to investigate the effects of polysulphone dialyzer membrane on serum IL-6 and hepcidin, including haemoglobin levels, in first-time patients undergoing five cycles of haemodialysis.
Patients and methods
Totally, 11 patients (male: five, female: six) were recruited for the present study after obtaining written informed consent. Their mean age was 57.4±13.4 years, and they were undergoing haemodialysis for the first time. Hepcidin, IL-6 and haemoglobin levels were determined before the first cycle and the fifth cycle and after the fifth cycle of haemodialysis. Pearson’s correlation coefficients were also determined.
Results and discussion
No statistically significant differences were observed before the first cycle and after the fifth cycle of haemodialysis in haemoglobin, IL-6 and hepcidin levels nor between pre-fifth and post-fifth cycle values, except for IL-6, which showed a significant mean reduction (P=0.04) from the pre-fifth cycle of 67.0 pg/ml to a mean value of 42.9 pg/ml (64.0% reduction). Analysis of variance showed no significant variation in the parameters studied, and no significant correlations between haemoglobin and IL-6, haemoglobin and hepcidin, and IL-6 and hepcidin were found.
Conclusion
In this short study of five-cycle haemodialysis, significant reduction in IL-6 with no significant change in hepcidin levels was found, even though severe anaemia was present. Kidney dysfunction probably results in decreased clearance of inflammatory markers and may not be improved by haemodialysis alone. Moreover, a different approach to reduce these markers is therefore warranted.
Article PDF
Similar content being viewed by others
References
Wald R, Yan AT, Perl J, et al. Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrol 2012; 13:3.
The National Institute of Health. Consensus conference statement. Morbidity and mortality of renal dialysis. An NIH consensus conference statement. Ann Intern Med 1994; 121:62–70.
Pozzoni P, Del Cecchio L, Pontorieo G, et al. Long-term outcome in hemodialysis morbidity and mortality. J Nephrol 2004; 17: S87–S95.
Memoli B, Postiglione L, Clanciaruso B, et al. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000; 58:417–424.
Ridker R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis, Br J Haematol 2001; 115:3–12
Pescoits-Filho R, Barany P, Lindholm B, et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17:1684–1688.
Beberashvili L, Sinuani I, Azar A, Yasur H, et al. IL-6 Levels, nutritional status and mortality on prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011; 6:2253–2283.
Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102:783–788.
Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to different diagnosis. Haematologica 2008; 93:90–97.
Darshan D, Anderson GJ. Interacting signals in the control of hepcidin expression. Biometals 2009; 22:77–87.
Nemeth E. Targeting the hepicidin-ferroportin axis in the diagnosis and treatment of anemia. Adv Hematol 2010; 2010:750643.
Ganz T. The role of hepcidin in iron sequestration during infection and in the pathogenesis of anemia of chronic disease. Isr Med Assoc J 2002; 4:1043–1045.
Zhang X, Rovin BH. Hepcidin expression by human monocytesin response to adhesion and pro-inflammatory cytokines. Biochim Biophys Acta 2010; 1800:1262–1267.
Nemeth E, et al. Interleukin-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271–1276.
Zaritsky J, Young B, Wang HJ, et al. Hepcidin, a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1051–1056.
Kerr P, Toussaint N. Dialysis membranes KHA-CARI dialysis adequacy. Nephrology (Carlton) 2013; 18:485–488.
Widiana IGR. Effect of polyethersulfone compared to cellulose diacetate dialyzer membrane on serum interleukin-6 and C-reactive protein levels in hemodialysis. J Penyakit Dalam 2008; 9:97–108
KDIGO. Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 91 (Suppl 3):763–994.
Covic A, Goldsmith DJ, Hill K, et al. Urea kinetic modelling—are any of the bedside Kt/V formulae reliable enough? Nephrol Dial Transplant 1998; 13:3138–3146.
Costa E, Pereira BJG, Rocha-Pereira P, et al. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol 2008; 28:677–683.
Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009; 22:70–77.
Ibrahim IA, Mohamad UM, Darwash HA, Rasheed AM. Impact in hepcidin, interleukin-6 and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients. Egypt J of Intern Med 2014; 26:6–14.
d’Angelo G. Role of hepcidin in the pathophysiology and 6diagnosis of anemia. Blood Res 2013; 48:10–15.
Maccio A, Maddedu C, Massa D, et al. Hemoglobin levels correlate with IL-6 levels in patient with advanced untreated advanced epithelial ovarian cancer—role of inflammation in cancer-related anemia. Blood 2005; 106:362–367.
Macdougall IC, Malysato J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:1681–1689.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hutagaol, S., Lubis, H.R., Zein, L.H. et al. Status of interleukin-6 and hepcidin levels in first-time haemodialysis patients. Egypt J Intern Med 29, 54–58 (2017). https://doi.org/10.4103/ejim.ejim_27_16
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/ejim.ejim_27_16